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Among the studies of oncogenes in human tumours, activation of
ras oncogene has been found to be the most common event in
various cancers including bladder cancers, breast cancers, colon
cancers, kidney cancers, liver cancers, lung cancers, ovarian
cancers, pancreatic cancers and gastric cancers (Yamashita et al,
1995; Muleahy et al, 1998; Caduff et al, 1999). In addition, activa-
tion of K-ras gene was found in more than 40% of colon cancer,
pancreatic cancers and lung cancers (Anker et al, 1997; Gao et al,
1997). Our previous study has also showed that mutations of the
K-ras gene were found in 55% of adrenocortical tumours and the
mutation hot spots were focused on codons 15, 16, 18 and 31 (Lin
et al, 1998), which were different from those (codons 12, 13 and
61) in other studies (Grendy et al, 1997). The K-ras gene encoded
a protein of 21 kDa, p21, which were consisted of 188 amino acids
(Santos and Nebreda, 1989). Ras protein as a critical relay switch
that controls signalling pathways connecting the cell surface with
the nucleus (Chen et al, 1996; Feliciello et al, 1996; Hughes et al,
1997). Ras protein is activated by growth factors, such as
epidermal growth factor (EGF), insulin and insulin growth factor
(IGF) (Leitner et al, 1997). It then triggers the activation of a
cascade of serine/threonine kinase, which includes Raf-1 and
MAPK (mitogen-activated protein kinase) (Porras and Santos,
1996). Activated MAPK then translocates to the nucleus where it
phosphorylates and activates transcription factors which, in turn,
cause changes in gene expression responsible for growth stimula-
tion (Winston and Hunter, 1995). Like other guanine nucleotide-
binding proteins, ras cycles between an active GTP-bound form
and an inactive GDP-bound form. The GDP-bound form is
converted to the GTP-bound form through a GDP/GTP exchange
reaction that is facilitated by guanine nucleotide-releasing factors
(Segal et al, 1993; Overbeck et al, 1995; Lin et al, 1996). On the
other hand, the GTP-bound form is converted to the GDP-bound
form by the intrinsic GTPase activity, which is accelerated by
GTPase-activating proteins (GAPs) (Molloy et al, 1995; Miao et
al, 1996; Wittinghofer et al, 1997). Since hydrolysis of GTP was
an important event in regulation of p21 activity, it was suggested
that mutation of ras gene might affect normal GTP hydrolysis.
Numerous researchers have analysed the ras gene and reported
that the mutation at codon 61 cause the mutant proteins to be unre-
sponsive to the stimulation by the GTPase activating proteins,
furthermore, increase the ras-transforming potential (Adari et al,
1988). However, other results showed that when a substitution
occurred at codons 12, 13 or 59 of the ras gene, the Ras protein
changed and furthermore lost its ability to bind with GTP
(Barbacid, 1987). Consequently, mutant Ras persists in an active,
GTP-bound state, leading to constitutive and deregulated stimula-
tion of growth regulatory process that contributes to the aberrant
growth properties of tumour cells (Downward, 1996). Our
previous findings indicated that K-ras gene was mutated at codons
15, 16, 18 and 31. Because these mutations occurred frequently in
the patients with adrenocortical tumours, we believe that they are
associated with the development of adrenal tumours. Therefore, it
is important to know whether these mutations affect the GTPase
activity of Ras in the presence or absence of GAP to understand
the mechanism of the carcinogenesis of adrenal tumours. In this
way, we first examined the intrinsic GTPase activity of mutant
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Summary Our previous studies have shown that seven out of 15 patients with adrenocortical tumours contained K-ras gene mutation. In
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Keywords: GTPase; K-ras mutants; functional adrenocortical tumours
1035
Received 7 July 1999
Revised 7 October 1999
Accepted 18 October 1999
Correspondence to: S-R Lin
British Journal of Cancer (2000) 82(5), 1035–1040
© 2000 Cancer Research Campaign
DOI: 10.1054/ bjoc.1999.1039, available online at http://www.idealibrary.com on K-Ras protein (p21K-Ras) and its GTPase activity in the GAP pres-
ence. We hope the results can provide a further understanding of
the correlation between K-ras oncogene and adrenal tumours.
MATERIALS AND METHODS
Construction of mutant K-ras expression plasmids
mRNA was extracted from tumour tissue and reverse transcribed
(RT) to cDNA with MMLV reverse transcriptase and oligo (dT).
Then, cDNA was amplified by polymerase chain reaction (PCR)
with primers specific for coding region and 5¢ and 3¢ non-coding
region of K-ras including KpnI and SacII site as follows: 5¢-
TTGGTACCCCTAAAAATGACTGAATATAAACTTGT-3¢ and
5¢-CGAGCTCGACCACTTGTACTAGTATGCC-3¢. A 615 bp
PCR product was amplified and inserted into the vectors
pBKCMV (Stratagen, La Jolla, CA, USA) to prepare K-ras gene
expression constructs for prokaryotic and eukaryotic cells. For
prokaryotic cells, the vector pBKCMV was used. This vector
contained a lac promoter which could regulate K-ras gene expres-
sion in Escherichia coli. In our experiments, wild-type and mutant
K-ras genes, including mutations at codons 15, 16, 18 and 60,
separately were cloned into the pBKCMV vector and named
as pKWTCMV, pK1516MCMV, pK568MCMV, pK60MCMV
(Table 1).
Purification of mutant K-ras protein synthesized by
E. coli
The bacterially synthesized K-Ras protein was purified as
described earlier (Gross et al, 1985). Ten grams of E. coli cells
were sonicated in 50 mM Tris–HCl, pH 8.0, 5 mM EDTA, 1 mM
phenylmethylsulphonyl fluoride (PMSF) (5 ml g–1 of cells), and
the sonicated cell extract was then centrifuged for 10 min at
4000  g to remove unbroken cells and cell debris. The particulate
fraction was pelleted by ultracentrifugation for 2 h at 3000 rpm.
The pellet was homogenized in an excess of buffer A (50 mM
Tris–HCl, pH 7.4, 5 mM 2-mercaptoethanol, 1 mM EDTA, 1 mM
PMSF) and the suspension was centrifuged as above. The pellet
was suspended in buffer A (2 ml g–1 of cells), and Ras protein was
solubilized by the addition of an equal volume of 7 M quanidine-
HCl. The clear supernatant containing Ras protein was obtained
after centrifugation for 2 h at 30 000 rpm and stored at –20°C
before use.
Construction of GAP expression plasmid
Using the PCR we constructed the expression plasmid for minimal
fragments of p120GAP: GAP-273 (residues Met714 – His986) from the
bovine brain cDNA. The oligonucleotides used were as follows:
5¢-CCGGAATTCCCGACCCCGCCGACCCCGATGGAAA
AAATCATGCC-3¢ and 5¢-AGCGGCCGCTTTATTAATGCTCT-
GTAGTGTCCGC-3¢. PCR products were isolated, digested with
EcoRI/Not I and ligated into the GST fusion vactor pGEX-4T-2
(Amersham, Pharmacia Biotech UK Ltd). The resulting plasmid,
pGEX-GAP, was transformed into E. coli strain TG1. The correct
orientation of the GAP cDNA was confirmed by sequencing.
Expression, purification and cleavage of GST-GAP
fusion protein
The expression of fusion protein was performed basically as
described by Guan and Dixon (1991). Twenty millilitres of an
overnight culture was inoculated into 1 litre of 2XYT (10 g yeast
extract, 16 g tryptone and 5 g sodium chloride (NaCl) in 1 litre)
containing 50 mg ml–1 ampicillin. The culture was incubated vigor-
ously at 37°C until an absorption of one at 600 nm was reached.
IPTG was then added and cells were harvested by centrifugation
and suspended in 10 ml PBST (2 mM EDTA, 0.1% b-mercapto-
ethanol, 0.2 mM PMSF and 5 mM benzamidine) after 3 h incuba-
tion. Cells were lysed and bacterial lysate was centrifuged at 4°C
to remove the insoluble fraction. One millilitre of the bacterial
supernatant containing soluble proteins was mixed with 2 ml 50%
(v/v) glutathione agarose beads and incubated 30 min at 4°C with
gentle shaking. The agarose beads were washed four times with
10 ml PBST. The fusion protein was eluted by competition with
glutathione using 2 ´ 2 min washes with 1 ml of 50 mM Tris
(pH 8.0) containing 10 mM glutathione. Free glutathione was
removed by dialysis against 50 mM Tris (pH 8.0), 150 mM NaCl,
0.1% b-mercaptoethanol. Approximately 2-mg fusion protein was
incubated with 4 mg of thrombin at room temperature for 20 min in
2 ml of thrombin cleavage buffer (50 mM Tris, (pH 8.0), 150 mM
NaCl, 2.5 mM calcium chloride (CaCl2), 0.1% b-mercap-
toethanol). Glutathione S-transferase and uncleaved fusion protein
were removed by directly adding 2 ml of glutathione agarose (50%
v/v) to the cleavage reaction. The sample was incubated for 30
min at 4°C and centrifuged for 10 min. The supernatant, which
contained purified GAP-273 protein was recovered. GTPase acti-
vating activity of GAP-273 was assayed by adding H-Ras (Santa
Cruz Biotechnology, Inc) expressed in E. coli.
Immunoblot
K-Ras protein from E. coli transformed with K-ras expression
plasmids was purified and electrophoresed through vertical slab
gels composed of 10% polyacrylamide containing 0.1% sodium
dodecyl sulphate (SDS) prepared in 3 mM Tris–HCl, pH 8.8.
Following electrophoresis, the protein was electroblotted to a
nitrocellulose membrane (Schleicher & Schusll GmbH, Dassel,
Germany). The membrane fixed with protein was incubated with
mouse monoclonal antibodies (mAbs) specific for the K-Ras
p21 product (25 mg ml–1) (Santa Cruz Biotechnology, Inc.), and
the excess unbounded antibodies were then washed off. The
membrane binding with the mouse mAbs was incubated with
a solution of secondary goat anti-mouse IgG conjugated with
alkaline phosphate (1:3000, Bio-Rad, Hercules, CA, USA). The
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Table 1 K-ras gene expression constructs from human adrenocortical
tumours and their gene products
K-ras mutant
Plasmid Vector Codon base Amino acid Protein
pKWTCMV pBKCMV Wild type p21BN
pK1516MCMV pBKCMV 15GGC®ACA Gly®Thr
16AAG®GAG Lys®Glu p21BM1
15GGC®ACG Gly®Thr
pK568MCMV pBKCMV 16AAG®AAA Lys®Lys
18GCC®GTC Ala®Val p21BM2
31GAA®CAA Glu®Gln
pK60MCMV pBKCMV 60GGT®TGT Gly®Cys p21BM3tagged Ras protein was detected by enhanced chemiluminescence
(ECL) detection system (Amersham, Pharmacia Biotech UK Ltd).
Blots was then exposed to Kodak XAR film (Eastman Kodak,
Rochester, NY, USA).
Measurement of GAP activity
GAP assay was measured as described by Li et al (19). Two pico-
moles of Ha-Ras-[g-32P]GTP (30 Ci mol–1, ICN) was incubated at
30°C with the indicated amounts of GAP-273 in 20 ml of a solution
containing 50 mM Tris–HCl (pH 8.0), 5 mM magnesium chloride
(MgCl2), 0.25 mM GTP, 5 mg ml–1 bovine serum albumin and 5%
glycerol. The reactions were quenched by keeping the sample on
ice. After the addition 0.5 ml of ice-cold washing buffer (20 mM
Tris–HCl (pH 8.0), 100 mM NaCl, 5 mM MgCl2), the sample was
passed through a nitrocellulose filter (0.45 mm, Schleicher &
Schusll GmbH, Dassel, Germany). The filter was washed three
times with 1 ml of ice-cold washing buffer, and the radioactivity
trapped on the filter was determined using a liquid scintillation
counter. The amount of GTP hydrolysed during the reaction was
determined as a decrease in the reactivity trapped on the filter. The
data were calculated from at least three independent experiments.
GTPase assay
Purification K-Ras protein (0.8 mg) was incubated with 60 mg of
K-Ras p21 mAb (Santa Cruz Biotechnology, Inc.) in 100 ml
of GTP buffer containing 0.1% Triton X-100, 50 mM PMSF and
0.3 mg ml–1 BSA at 0°C for 60 min. Then, 2 ml of protein
A-Sepharose beads (Amersham, Pharmacia Biotech UK Ltd),
coated with rabbit anti-rat IgG and equilibrated in GTP
buffer/0.1% Triton, was added and the sample was mixed for 25
min at 4°C. The beads were washed extremely with GTP buffer
containing 0.12 M (NH4)2SO4 and 0.1 mg ml–1 BSA. The beads
were then resuspended in 120 ml of this latter buffer containing
25 mM [a-32P]-GTP (15 TBeq mmol–1; Amersham, Pharmacia
Biotech UK Ltd) activity was measured by removing sample of the
beads at each time, washing in GTP buffer/0.01% Triton and
elution at 65°C with EDTA–SDS then layer chromatography
(TLC) sample buffer. TLC analysis was performed as described
below. To monitor GTPase activity stimulated by GAP. Twenty-
five microlitres of the solution containing (8,5¢-3H) a-32P-GTP-
bound  Ras protein was incubated with appropriate amount of
GAP-273 at 30°C. At different time, 5 ml of the mixture was mixed
taken to with 5 ml 0.5% SDS, 10 mM EDTA, 100 mM GTP and 100
mM GDP and taken heated to 80°C for 5 min. The mixture was
immediately blotted on PEI-cellulose TLC plates and chro-
matographed in 0.5 M lithium chloride and 1 M formic acid
solution. GTP and GDP spots were then cut off from the TLC plate
separately and the radioactivity was determined. The rate of GTP
hydrolysis was obtained from semilogarthnic plotting of the
amount of bound GTP against time.
RESULTS
The translational products of mutant K-ras gene constructs from
human adrenocortical tumours made by E. coli, were showed in
the 12.5% SDS polyacrylamide gel in Figure 1A. Then, 3.5 M
guanidine–HCl was used to extract the K-Ras protein from the
washed particulate fraction and a few other proteins might also be
extracted. However, the intensity of the bands in Figure 1 showed
that 85% of the proteins were K-Ras proteins. Further immunoblot
analysis proved that those proteins could interact with mAbs
specific for K-Ras p21 proteins, confirming that they were p21K-Ras
proteins (Figure 1B). Comparison with the M.W. marker revealed
that these K-Ras protein were 23 000 dalton.
The 273-residue fragment from p120GAP from Met714 to His986
could be expressed in E. coli as a glutathione S-transferase (GST)
fusion protein. Figure 2 shows that the protein was isolated as GST
fusion protein and cleaved from GST by thrombin. It remained
soluble after purification. The specific activity of GAP-273 for
GTPase activity of K-ras mutants 1037
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Figure 1 SDS-PAGE and Western blot analysis of the translational products of mutant K-ras gene constructs from human adrenocortical tumours made
by E. coli. K-Ras protein from E. coli transformed with pBKCMV (lane 1), pKWTCMV (lane 2), pK1516MCMV (lane 3), pK568MCMV (lane 4) or pK60MCMV
(lane 5) were separated on a 10% polyacrylamide gel stained with Coomassie blue (A). The gel was followed by electroblotting to a nitrocellulose membrane.
The blotted filter was probed with monoclonal antibody to K-Ras p21 protein. The filter were probed with a secondary alkaline phosphotase-conjugated goat
anti-mouse IgG. The tagged K-Ras protein was detected by ECL detection system, then exposed to Kodak XAR film (B). Lane M, molecular weight standardcatalysed hydrolysis of Ha-Ras GTP was shown in Figure 3. In
Figure 3, GAP-273 purified from GST fusion protein is actually
able to catalyse the hydrolysis of Ras GTP. Therefore, we used
this purified GAP-273 protein to regulate the GTPase activity of
mutant K-Ras proteins in our experiments.
The GTPase activities of these K-Ras proteins were measured
both in the absence and presence of GAP-273. When the four
different K-Ras proteins were analysed for their intrinsic GTPase
activity, we found that the difference of K-Ras proteins of similar
purity and quantity were shown in GTPase reaction, however, they
have very high reproductivity. p21BN K-Ras protein, which is the
wild-type K-Ras protein, reacted very similarly to p21BM1 and
p21BM2 in intrinsic GTPase activity in which about 20% of the
substrate GTP is hydrolysed by p21BN protein after 1.5 h (Figure
4). However, GTPase reactions of p21BM3 were 10 times lower
than that of p21BN (Figure 5).
K-Ras mutant protein, p21BM3 and wild-type p21BN were
purified with the same procedure and analysed by immunoprecipi-
tation of intrinsic GTPase activity, suggesting that they should
have similar purity and the same experimental errors. However,
the GTPase activity of the two proteins were 8–15 times different.
Therefore, we thought that these GTPase reaction were actually
caused by K-Ras protein. In addition, other recombinant protein of
similar size made in E. coli under the control of the same expres-
sion plasmid and solubilized from the particulate fraction of bacte-
rial cell extracts in an identical manner to that used for K-Ras
protein had minor contaminants similar to those in the K-Ras
protein preparations yet exhibited no trace of GTPase activity. The
above results indicated that the difference in GTPase activity was
actually caused by purified K-Ras protein, only the K-Ras protein
mutated at codon 60 from human adrenocortical tumour influ-
enced the intrinsic GTPase activity.
In the GTPase activity assay with the GAP stimulation, the
mutant p21BM1 K-Ras protein mutated at codon 15 and 16, in
both the absence and presence of purified GAP-273 protein, it had
the same GTPase activity as wild-type p21BN K-Ras protein.
Although the intrinsic GTPase activity of p21BM3 K-Ras protein,
which mutated at codon 60, decreased the intrinsic GTPase
activity, the GAP-stimulated GAPase activity of this mutant
protein was similar to that of the wild-type K-Ras protein. By
contract, the mutant K-Ras protein, which mutated at codons 15,
16, 18 and 31, had the same intrinsic GTPase activity to this of
wild-type K-Ras protein, but their GTPase activity was signifi-
cantly lower than wild-type K-Ras protein after stimulation with
GAP. Thus, we concluded that of the mutant K-Ras proteins from
human adrenocortical tumours, only the mutant K-Ras protein
which mutated at codons 15, 16, 18 and 31, influence GAP-
sensitivity.
DISCUSSION
The K-ras gene has two alternative 3¢ exons designated 4A and 4B
(Capon et al, 1983). p21K-rasA and p21K-rasB are similar but different
in the 24/25 C terminal residues. Numerous reports have shown
that K-rasB appears to be ubiquitously expressed (Slamon and
Cline, 1984; Leon et al, 1987); in contrast, the expression of K-
rasA is induced during differentiation of pluripotent embryonal
stem cells in vitro (Pells et al, 1997). In addition, our previous
study of human adrenocortical tumours showed that mutant and
expressed K-ras genes are mainly K-rasB gene. Therefore, we
cloned K-rasB cDNA from tumour cells into a vector and then
transformed the K-ras gene constructs into E. coli. The K-Ras
proteins expressed in E. coli transformed with K-ras gene
constructs were observed through SDS-gel electrophoresis. The
results showed that these K-Ras proteins migrate with an apparent
molecular weight slightly larger than that of natural p21Ras protein.
This is probably due to the inability of E. coli to carry out the post-
translational modification with p21Ras undergoes in mammalian
cells (Lantenberger et al, 1983).
In the cell the conformational state of guanine nucleotide
binding proteins is regulated by two kinds of interacting mole-
cules, guanine nucleotide exchange factors and GTPase activating
proteins (called GAPs). Three specific GAPs for p21Ras were
p120GAP (the prototype of this class of proteins and the first one to
be isolated) (Vogel et al, 1988; Lim et al, 1992), neurofibromin
(NF1) (Hattori et al, 1992) and a mammalian homologue (GAP1m)
1038 S-R Lin et al
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Figure 2 Expression of the minimal fragment of p120GAP. GAP-273 were
expressed as GST fusion protein using improved GST expression vector and
purified as seen here in an SDS-polyacrylamide gel stained with Coomassie
blue. Protein in lane 1 was the uncleaved 56-kDa GST-GAP fusion protein.
Lane 2 represents the reaction mixture of GST–GAP fusion protein after
thrombin cleavage. The GAP-273 (30 kDa) in lane 3 and glutathione S-
transferase (26 kDa) in lane 4 are major components of the reaction mixture
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Figure 3 Time course of the GAP-273-stimulated GTP hydrolysis by H-Ras
protein. Two picomols of Ha-Ras-[g-32P]GTP were incubated at 30°C for
indicated periods of time with (open symbols) or without (filled symbols)
GAP-273. The reaction mixture was passed through a nitrocellulose filter.
The filter was washed and the radioactivity trapped on the filter was
determined using a liquid scintillation counter. The amount of GTP
hydrolysed was determined as a decrease in the reactivity trapped on the
filter. The data are shown as relative percentagesof the Drosophilic GAP1. p120GAP and NF1 protein can be distin-
guished with respect to their catalytic properties (Martin et al,
1990; Xu et al, 1990; Nur-E-Kamal and Maruta, 1992). p120GAP
increases the GTPase reaction of p21Ha-Ras more than tenfold
catalytic activity for Ras GTP, whereas NF1 protein has been
reported to have a lower activity but a higher affinity. In this study,
we demonstrated that GAP-273 (codons 174–986) could stimulate
the GTP hydrolysis of Ha-Ras protein. This is consisted with the
result made by Ahmadian et al (1996). In 1996, Ahmadian et al
confirmed that the specific activity of GAP-273 for catalysed
hydrolysis of Ras bound GTP was almost the same as that
measured with full-length p120GAP. Therefore, we used GAP-273
as the GAP of mutant K-Ras in this study.
Regarding the analysis of GTPase activity and GAP sensitivity,
the results showed that only mutation at codon 60 influenced
intrinsic GTPase activity. This may be due to the fact that codon 60
(Gly) is the only amino acid without a branch among the amino
acids on phosphate binding region (codons 57–63) (Sung et al,
1995). In the mutant K-Ras protein, the cysteine substitution
caused this amino acid (Gly) to add a sulphur, which affected its
conformation and furthermore affected its binding with GAP, then
enhancing the activity of GTPase (Boriack-Sjodin et al, 1998). The
same phenomena was also observed in the K-Ras protein with
mutation at codon 28 (Powers et al, 1989). On the other hand, the
mutant K-Ras protein with mutation at codons 15, 16, 18 and 31
had lower GAP sensitivity than normal. These results can be
explained by the reports of Sigal et al (1986), Powers et al (1989)
and Shirouzu et al (1992). In 1986, Sigal et al found p21 protein
Lys-16 was the decision site of the GTP/GDP-binding site. If Lys-
16 is replaced by Asn, the affinity between GTP and GDP will
decrease 100 times, without affecting GTP/GDP-binding speci-
ficity. In 1989, Powers et al designed a mutant p21 protein with
Ala instead of Gly-15 for studying the characteristics of the p21
protein. The results showed that this alteration could also affect the
normal functions of the p21 protein. In addition, Shirouzu et al
(1992) found that Ras protein with Glu-31®Lys mutation was
found to have drastically decreased GAP sensitivity. Thus they
GTPase activity of K-ras mutants 1039
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Figure 4 Time course of the GAP-273-stimulated GTP hydrolysis of wild-
type K-Ras protein, p21BN. Shown is the GTP hydrolysis reaction catalysed
by recombinant K-Ras protein, p21BN in the absence and presence of GAP-
273. The reaction was conducted at 30°C and samples were taken at the
indicated times. The reaction products were analysed by TLC, followed by
autoradiography (A) and quantification of the radioactive GTP and GDP spots
using a PhosphoImager (Molecular Dynamics) (B)
0 20 40 60 80 100
Time (min)
0
25
50
75
100
G
T
P
 
h
y
d
r
o
l
y
s
i
s
 
(
%
)
p21BN
p21BN + GAP
p21BM1 + GAP
p21BM1
p21BM2 + GAP
p21BM2
p21BM3 + GAP
p21BM3
Figure 5 Time course of the GAP-273-stimulated GTP hydrolysis of mutant K-Ras proteins. The GTPase activity was determined by 25 ml of the solution
containing (8, 5¢-3H) a-32 P-GTP bound Ras protein was incubated with (filled symbol) or without (open symbol) GAP-273 at 30°C. At different time, 5 ml of the
mixture was analysed by TLC. GTP and GDP spots were then cut off from the TLC plate separately and the radioactivity was determined. The rate of GTP
hydrolysis was obtained from semilogarthnic plotting of the amount of bound GTP against timeconcluded that p21 Ras protein Glu-31 is an important residue for
the simulation of GTPase activity by GAPRas. However, the K-Ras
protein with mutation at codons 15 and 16 from another tumour
did not reveal a decrease in GAP sensitivity. This may be caused
by different amino acid substitution between the two mutant K-
Ras protein.
In this study, we observed that mutant K-ras gene from human
adrenocortical tumour has indeed decreased the GTPase activity of
K-Ras protein. Our advanced study showed that when the normal
adrenocortical cell transfected with mutant K-ras expression
plasmids derived from human adrenocortical cells by electropora-
tion, the levels of cortisol secreted by transfected cells were 15–25
times higher than normal cells (Lin et al, 1999). However, the
mechanisms by which K-Ras protein affects the adrenocortical
tumour development needs more study.
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